MNKD Stock — MannKind Corporation: Cash, EV, Pipeline

Share price

$3.54

Market cap

$1,138.3M

Cash

$111.1M

Enterprise value

$1,346.3M

Balance sheet

Cash	$111.1M
Debt	$319.1M
Net cash	-$208.0M
Enterprise value	$1,346.3M
Basic shares	309.9M shares
Fully diluted shares	354.4M shares
Fully diluted market cap	$1,254.4M
Cash per share	$0.36

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading MNKD daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	Technosphere Insulin	Phase 2	Type 1 Diabetes Mellitus	—
Feb 10 - Mar 23	Nintedanib Dry Powder Inhalation	Phase 2	Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Afrezza

Approved · Active Modality: Technosphere inhalation powder (insulin human)

Target insulin receptor

Partnerships Cipla (India launch partner); Amphastar (insulin supply)

Indications

diabetes (mealtime insulin) (Approved)

Catalysts

— May 29, 2026

Status note Commercial product; sBLA for children and adolescents assigned PDUFA May 29, 2026.

Furoscix

Approved · Active Modality: furosemide injection (on-body infusor)

Target NKCC2

Indications

heart failure (congestion) (Approved)

Status note Commercial product; ReadyFlow autoinjector sNDA submitted 2025.

V-Go

Approved · Active Modality: wearable mechanical basal-bolus insulin delivery device

Partnerships Zealand Pharma (acquired May 2022)

Indications

diabetes (Approved)

Status note FDA 510(k) cleared 2010; commercial since 2012.

Tyvaso DPI

Approved · Active Modality: treprostinil inhalation powder (Technosphere)

Target prostacyclin (IP) receptor

Partnerships United Therapeutics (development and marketing partner; 10% royalty on net sales)

Indications

pulmonary arterial hypertension (PAH) (Approved)
pulmonary hypertension associated with interstitial lung disease (PH-ILD) (Approved)

Status note FDA approved May 2022; commercialized by United Therapeutics.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Technosphere Insulin
Lead indication	Type 1 Diabetes Mellitus
Lead phase	Phase 2
Active trials	2
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07224321	Phase 2	Recruiting	Sponsor	MNKD	—	Type 1 Diabetes Mellitus	—
NCT07679893	Phase 2	Recruiting	Sponsor	MNKD	—	Idiopathic Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)	—
NCT06535789	Phase 3	Recruiting	Collaborator	Jaeb Center for Health Research	—	Diabetes, Gestational; Pregnancy Complications; Glucose Metabolism Disorders	—
NCT06880835	Not disclosed	Recruiting	Collaborator	Jaeb Center for Health Research	—	Diabetes Mellitus, Type 1	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Mannkind Corporation on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	6,600,000	+700,000	0.61%	2026-08-14
Braidwell LP	3,458,429	+3,458,429	0.54%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

MNKD — MannKind Corporation

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders